Pharmacology

Positive Phase 2 Results For Lipid-Lowering PCSK9 Antibody

Sanofi and Regeneron Pharmaceuticals, Inc. today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 (Study 1003, NTC01266876) in patients with heterozygous familial hypercholesterolemia (heFH). SAR236553/REGN727 is a subcutan ...

Article - Anna Ohlden - May 26 2012 - 11:39pm

Positive CHMP Opinion For Perampanel In Focal Epilepsy

Eisai announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Fycompa(R) (perampanel) as an adjunctive treatment of focal seizures, with or without second ...

Article - Anna Ohlden - May 29 2012 - 2:30am

Antioxidants For Autism

A specific antioxidant supplement containing N-Acetylcysteine, or NAC may be an effective therapy for some features of autism, according to a pilot trial from the Stanford University School of Medicine and Lucile Packard Children's Hospital that invo ...

Article - News Staff - May 30 2012 - 3:30pm

Positive Phase 2 Study Results For Tivantinib In Previously Treated Hepatocellular Carcinoma

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in he ...

Article - Anna Ohlden - Jun 2 2012 - 3:05pm

When Kids Need Meds: A Must Have For Parents Of Special Needs Kids

Parents of children with neurological conditions and disorders and mental health issues are often faced with the frightening and difficult decision of whether to medicate for specific issues and behaviors. Parents are already stressed, worried, and expecti ...

Article - Kim Wombles - Jun 5 2012 - 10:10am

10-Year Data Evaluating Adalimumab For Patients With Moderate-to-Severe Rheumatoid Arthritis

BERLIN, June 6, 2012-- Abbott today announced results from two long-term, open-label studies, which evaluated the results of HUMIRA® (adalimumab) treatment for up to 10 years in patients with long-standing, moderate-to-severe rheumatoid arthritis (RA). Th ...

Article - Anna Ohlden - Jun 6 2012 - 10:06am

5-Year Data For Ustekinumab Show Consistent Efficacy And Safety For Moderate To Severe Plaque Psoriasis

HIGH WYCOMBE, England, June 6, 2012 -- Findings from a psoriasis clinical development program for a biologic following patients continuously for five years provide insights on the long-term response and safety profile of ustekinumab. New efficacy and saf ...

Article - Anna Ohlden - Jun 6 2012 - 11:30am

In Study, Male Sexual Dysfunction Improved With Saw Palmetto Extract

A natural treatment made from Saw Palmetto berries can have a significant effect in reducing sexual dysfunction in men with prostate problems, a new clinical trial found. A male libido study carried out by Swiss-based herbal specialists A. Vogel used extr ...

Article - Anna Ohlden - Jun 14 2012 - 4:00am

Positive Phase 2 Study Results For Tivantinib In Previously Treated Hepatocellular Carcinoma

ArQule, Inc. and Daiichi Sankyo Co., Ltd. announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatoc ...

Article - Anna Ohlden - Jun 13 2012 - 2:00pm

Positive Phase 2 Study Results For Tivantinib In Hepatocellular Carcinoma